-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Share
Listen to the news

Gainers

  • iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million.
  • Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 22.53% to $1.02.
  • Pharvaris (NASDAQ:PHVS) stock rose 19.12% to $41.99. The company's market cap stands at $2.4 billion.
  • Roivant Sciences (NASDAQ:ROIV) stock rose 18.49% to $41.39. The company's market cap stands at $25.2 billion.
  • Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 9.83% to $10.72. The company's market cap stands at $97.9 million.
  • Jin Medical International (NASDAQ:ZJYL) shares increased by 9.08% to $2.27. The market value of their outstanding shares is at $16.2 million.

Losers

  • Dyne Therapeutics (NASDAQ:DYN) shares fell 28.8% to $17.3 during Tuesday's pre-market session. The company's market cap stands at $4.5 billion.
  • bioAffinity Technologies (NASDAQ:BIAF) stock declined by 24.69% to $11.5. The company's market cap stands at $9.1 million.
  • Onconetix (NASDAQ:ONCO) shares fell 18.63% to $0.83. The market value of their outstanding shares is at $4.4 million.
  • Lexaria Bioscience (NASDAQ:LEXX) shares fell 17.96% to $11.61. The company's market cap stands at $23.3 million.
  • Jaguar Health (NASDAQ:JAGX) stock fell 17.25% to $0.49. The company's market cap stands at $3.0 million.
  • Pomdoctor (NASDAQ:POM) stock declined by 15.67% to $0.7. The company's market cap stands at $7.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending